Share Price and Basic Stock Data
Last Updated: December 19, 2025, 10:00 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Vivimed Labs Ltd, a player in the pharmaceutical sector, has faced significant challenges over the past few years. The company reported a decline in sales, with revenues dropping from ₹861 Cr in FY 2021 to just ₹187 Cr in FY 2023. This downward trajectory has continued into FY 2024, where revenues stood at ₹149 Cr, and the trailing twelve months (TTM) figure is a mere ₹108 Cr. Such a steep decline raises concerns about the company’s ability to maintain market share and operational viability. The quarterly sales figures reflect this struggle, with the latest report showing ₹33.64 Cr in September 2023, a stark contrast to ₹50.11 Cr in June 2022. The volatility in sales can be attributed to various factors, including market competition and operational inefficiencies, which may hinder the company’s recovery and growth prospects.
Profitability and Efficiency Metrics
Profitability remains a critical concern for Vivimed Labs. The company has consistently reported negative operating profits, with an operating profit margin (OPM) of -1.31% in the latest quarter, indicative of ongoing operational issues. In FY 2023, the net profit plunged to -₹329 Cr, reflecting a severe downturn from the previous periods. The interest coverage ratio (ICR) of -2.94x signifies that the company’s earnings are insufficient to cover its interest obligations, raising red flags for investors. Furthermore, the return on capital employed (ROCE) has been notably poor, standing at -5.63% for FY 2025. The cash conversion cycle (CCC) of 351 days suggests inefficiencies in managing working capital, which could further strain liquidity and operational performance. These figures paint a troubling picture, suggesting that Vivimed is grappling with both profitability and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Vivimed Labs reveals significant vulnerabilities, particularly concerning its debt levels and reserves. As of FY 2025, the company reported borrowings of ₹384 Cr, against reserves that have plummeted to -₹65 Cr. This negative reserve position indicates that the company has accumulated losses that outstrip its equity, a concerning sign for long-term sustainability. The total liabilities have decreased to ₹921 Cr, but the total debt to equity ratio stands at a staggering -10.70x, highlighting an alarming level of indebtedness relative to shareholder equity. Additionally, the current ratio of 0.80x suggests potential liquidity issues, as the company may struggle to meet its short-term obligations. Such financial ratios reflect a precarious position, necessitating careful management of debt and operational restructuring.
Shareholding Pattern and Investor Confidence
Investor confidence in Vivimed Labs appears shaky, as evidenced by the shareholding pattern. Promoter holdings have dwindled from 20.94% in early 2023 to just 7.76% by June 2025, which could signal a lack of confidence from those who are most familiar with the company’s operations. Conversely, public ownership has surged to 90.47%, indicating that retail investors are absorbing the shares that promoters have shed. However, the presence of foreign institutional investors (FIIs) remains minimal at 1.64%, suggesting that institutional confidence is lacking. This shift in ownership dynamics could lead to increased volatility in the stock price, as retail investors may react more emotionally to news and market changes. The dwindling promoter stake raises questions about the future direction of the company and its strategic priorities.
Outlook, Risks, and Final Insight
Looking ahead, Vivimed Labs faces a series of challenges that could impact its recovery trajectory. The persistent decline in revenues and profitability, coupled with a fragile balance sheet, suggests that the company must undertake significant operational and financial restructuring to regain stability. Moreover, the high levels of debt and negative reserves pose inherent risks, particularly in an environment where interest rates may rise. Investors should be cautious, as the company’s ability to navigate these challenges will be crucial for any potential turnaround. On the flip side, if Vivimed can streamline operations, improve its cash conversion cycle, and stabilize its financial position, there may be opportunities for recovery. However, the current landscape suggests that investors need to weigh the risks carefully before considering an investment in Vivimed Labs, as the path to recovery appears fraught with uncertainty.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 147 Cr. | 116 | 235/84.3 | 32.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.38 Cr. | 1.77 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,405 Cr. | 405 | 479/192 | 91.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.7 Cr. | 48.2 | 89.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 48.3 Cr. | 33.0 | 33.0/17.0 | 115 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,165.58 Cr | 1,151.77 | 52.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.11 | 44.22 | 55.74 | 37.03 | 35.35 | 33.64 | 41.46 | 38.62 | 29.37 | 24.77 | 36.51 | 25.61 | 21.39 |
| Expenses | 58.69 | 53.53 | 60.87 | 201.32 | 35.68 | 39.54 | 40.19 | 67.09 | 40.37 | 25.41 | 35.46 | 28.08 | 21.67 |
| Operating Profit | -8.58 | -9.31 | -5.13 | -164.29 | -0.33 | -5.90 | 1.27 | -28.47 | -11.00 | -0.64 | 1.05 | -2.47 | -0.28 |
| OPM % | -17.12% | -21.05% | -9.20% | -443.67% | -0.93% | -17.54% | 3.06% | -73.72% | -37.45% | -2.58% | 2.88% | -9.64% | -1.31% |
| Other Income | 0.08 | 0.15 | 0.05 | 0.68 | 0.11 | 2.20 | 0.04 | 7.63 | 0.06 | 0.03 | 0.07 | 4.22 | 0.38 |
| Interest | 9.31 | 8.85 | 9.22 | 8.52 | 10.66 | 11.89 | 13.21 | -33.33 | 0.30 | 0.43 | 0.48 | 1.74 | 0.58 |
| Depreciation | 4.45 | 4.02 | 4.02 | 95.92 | 4.70 | 4.70 | 4.70 | 5.84 | 4.01 | 4.10 | 6.62 | 5.50 | 5.01 |
| Profit before tax | -22.26 | -22.03 | -18.32 | -268.05 | -15.58 | -20.29 | -16.60 | 6.65 | -15.25 | -5.14 | -5.98 | -5.49 | -5.49 |
| Tax % | -0.22% | 0.00% | 0.00% | -0.77% | 0.00% | 0.00% | -3.31% | 20.90% | 0.00% | 0.00% | 0.00% | 2.19% | 0.00% |
| Net Profit | -22.20 | -22.03 | -18.31 | -265.99 | -15.58 | -20.30 | -16.05 | 5.26 | -15.25 | -5.14 | -5.98 | -5.60 | -5.49 |
| EPS in Rs | -2.68 | -2.66 | -2.21 | -32.08 | -1.88 | -2.45 | -1.94 | 0.63 | -1.84 | -0.62 | -0.72 | -0.68 | -0.66 |
Last Updated: August 20, 2025, 1:20 am
Below is a detailed analysis of the quarterly data for Vivimed Labs Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 21.39 Cr.. The value appears to be declining and may need further review. It has decreased from 25.61 Cr. (Mar 2025) to 21.39 Cr., marking a decrease of 4.22 Cr..
- For Expenses, as of Jun 2025, the value is 21.67 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 28.08 Cr. (Mar 2025) to 21.67 Cr., marking a decrease of 6.41 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.28 Cr.. The value appears strong and on an upward trend. It has increased from -2.47 Cr. (Mar 2025) to -0.28 Cr., marking an increase of 2.19 Cr..
- For OPM %, as of Jun 2025, the value is -1.31%. The value appears strong and on an upward trend. It has increased from -9.64% (Mar 2025) to -1.31%, marking an increase of 8.33%.
- For Other Income, as of Jun 2025, the value is 0.38 Cr.. The value appears to be declining and may need further review. It has decreased from 4.22 Cr. (Mar 2025) to 0.38 Cr., marking a decrease of 3.84 Cr..
- For Interest, as of Jun 2025, the value is 0.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.74 Cr. (Mar 2025) to 0.58 Cr., marking a decrease of 1.16 Cr..
- For Depreciation, as of Jun 2025, the value is 5.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.50 Cr. (Mar 2025) to 5.01 Cr., marking a decrease of 0.49 Cr..
- For Profit before tax, as of Jun 2025, the value is -5.49 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded -5.49 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 2.19% (Mar 2025) to 0.00%, marking a decrease of 2.19%.
- For Net Profit, as of Jun 2025, the value is -5.49 Cr.. The value appears strong and on an upward trend. It has increased from -5.60 Cr. (Mar 2025) to -5.49 Cr., marking an increase of 0.11 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.66. The value appears strong and on an upward trend. It has increased from -0.68 (Mar 2025) to -0.66, marking an increase of 0.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:24 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,351 | 1,380 | 1,346 | 1,462 | 1,186 | 1,315 | 1,059 | 861 | 237 | 187 | 149 | 116 | 104 |
| Expenses | 1,139 | 1,156 | 1,111 | 1,057 | 971 | 1,135 | 1,049 | 830 | 245 | 374 | 182 | 129 | 107 |
| Operating Profit | 212 | 224 | 234 | 404 | 215 | 180 | 10 | 32 | -8 | -187 | -33 | -13 | -3 |
| OPM % | 16% | 16% | 17% | 28% | 18% | 14% | 1% | 4% | -3% | -100% | -22% | -11% | -3% |
| Other Income | 8 | 6 | 11 | 8 | 10 | 23 | 8 | 10 | 1 | 1 | 10 | 4 | 5 |
| Interest | 67 | 86 | 84 | 68 | 82 | 70 | 61 | 56 | 40 | 36 | 3 | 3 | 4 |
| Depreciation | 66 | 66 | 61 | 58 | 56 | 67 | 67 | 56 | 18 | 108 | 20 | 20 | 22 |
| Profit before tax | 87 | 78 | 100 | 286 | 86 | 66 | -109 | -70 | -65 | -331 | -46 | -32 | -24 |
| Tax % | 24% | 7% | 16% | 25% | 11% | 13% | -0% | 3% | 4% | -1% | -1% | 0% | |
| Net Profit | 66 | 72 | 84 | 214 | 76 | 57 | -109 | -72 | -68 | -329 | -45 | -32 | -24 |
| EPS in Rs | 8.20 | 8.90 | 10.33 | 26.41 | 9.44 | 6.95 | -13.16 | -8.67 | -8.16 | -39.62 | -5.48 | -3.85 | -2.94 |
| Dividend Payout % | 7% | 0% | 0% | 2% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 9.09% | 16.67% | 154.76% | -64.49% | -25.00% | -291.23% | 33.94% | 5.56% | -383.82% | 86.32% | 28.89% |
| Change in YoY Net Profit Growth (%) | 0.00% | 7.58% | 138.10% | -219.25% | 39.49% | -266.23% | 325.17% | -28.39% | -389.38% | 470.15% | -57.43% |
Vivimed Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -22% |
| 5 Years: | -36% |
| 3 Years: | -21% |
| TTM: | -24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 15% |
| TTM: | 52% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -21% |
| 5 Years: | -25% |
| 3 Years: | -20% |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:12 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 480 | 479 | 505 | 718 | 885 | 602 | 493 | 415 | 348 | 23 | -22 | -52 | -65 |
| Borrowings | 958 | 1,076 | 1,015 | 1,011 | 1,149 | 1,280 | 1,268 | 326 | 359 | 379 | 377 | 376 | 384 |
| Other Liabilities | 404 | 327 | 519 | 317 | 343 | 431 | 432 | 532 | 543 | 658 | 579 | 580 | 588 |
| Total Liabilities | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 924 |
| Fixed Assets | 808 | 813 | 814 | 879 | 1,035 | 965 | 1,045 | 502 | 520 | 436 | 418 | 408 | 393 |
| CWIP | 38 | 90 | 94 | 76 | 65 | 122 | 89 | 60 | 40 | 21 | 21 | 17 | 21 |
| Investments | 0 | 3 | 3 | 3 | 3 | 3 | 86 | 199 | 199 | 199 | 168 | 168 | 168 |
| Other Assets | 1,011 | 992 | 1,144 | 1,104 | 1,290 | 1,239 | 990 | 529 | 507 | 421 | 343 | 328 | 342 |
| Total Assets | 1,858 | 1,898 | 2,055 | 2,062 | 2,394 | 2,329 | 2,210 | 1,289 | 1,266 | 1,076 | 950 | 921 | 924 |
Below is a detailed analysis of the balance sheet data for Vivimed Labs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Reserves, as of Sep 2025, the value is -65.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -52.00 Cr. (Mar 2025) to -65.00 Cr., marking a decline of 13.00 Cr..
- For Borrowings, as of Sep 2025, the value is 384.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 376.00 Cr. (Mar 2025) to 384.00 Cr., marking an increase of 8.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 588.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 580.00 Cr. (Mar 2025) to 588.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 924.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 921.00 Cr. (Mar 2025) to 924.00 Cr., marking an increase of 3.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 393.00 Cr.. The value appears to be declining and may need further review. It has decreased from 408.00 Cr. (Mar 2025) to 393.00 Cr., marking a decrease of 15.00 Cr..
- For CWIP, as of Sep 2025, the value is 21.00 Cr.. The value appears strong and on an upward trend. It has increased from 17.00 Cr. (Mar 2025) to 21.00 Cr., marking an increase of 4.00 Cr..
- For Investments, as of Sep 2025, the value is 168.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 168.00 Cr..
- For Other Assets, as of Sep 2025, the value is 342.00 Cr.. The value appears strong and on an upward trend. It has increased from 328.00 Cr. (Mar 2025) to 342.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 924.00 Cr.. The value appears strong and on an upward trend. It has increased from 921.00 Cr. (Mar 2025) to 924.00 Cr., marking an increase of 3.00 Cr..
However, the Borrowings (384.00 Cr.) are higher than the Reserves (-65.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -746.00 | 223.00 | 233.00 | 403.00 | 214.00 | 179.00 | 9.00 | -294.00 | -367.00 | -566.00 | -410.00 | -389.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 94 | 87 | 88 | 50 | 85 | 99 | 86 | 46 | 134 | 145 | 203 | 233 |
| Inventory Days | 249 | 244 | 294 | 329 | 411 | 397 | 396 | 263 | 573 | 216 | 327 | 358 |
| Days Payable | 106 | 107 | 98 | 122 | 154 | 207 | 179 | 35 | 100 | 74 | 225 | 240 |
| Cash Conversion Cycle | 237 | 224 | 285 | 258 | 342 | 288 | 303 | 274 | 607 | 286 | 305 | 351 |
| Working Capital Days | 57 | 43 | 58 | 55 | 121 | 68 | 216 | 77 | 195 | -15 | -171 | -255 |
| ROCE % | 12% | 11% | 12% | 22% | 9% | 7% | -3% | -1% | -3% | -52% | -9% | -8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| Diluted EPS (Rs.) | -3.74 | -5.32 | -39.62 | -7.92 | -8.42 |
| Cash EPS (Rs.) | -1.42 | -3.08 | -26.55 | -5.95 | -1.98 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -8.82 | -5.24 | 0.17 | 39.35 | 47.47 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -4.24 | -0.65 | 4.75 | 43.93 | 52.05 |
| Revenue From Operations / Share (Rs.) | 14.02 | 17.98 | 22.57 | 28.62 | 103.90 |
| PBDIT / Share (Rs.) | -1.05 | -2.13 | -22.47 | -0.81 | 4.77 |
| PBIT / Share (Rs.) | -3.49 | -4.53 | -35.55 | -3.02 | -1.93 |
| PBT / Share (Rs.) | -3.84 | -4.82 | -39.88 | -7.82 | -8.43 |
| Net Profit / Share (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| NP After MI And SOA / Share (Rs.) | -3.85 | -5.48 | -39.62 | -8.16 | -8.67 |
| PBDIT Margin (%) | -7.46 | -11.82 | -99.59 | -2.86 | 4.58 |
| PBIT Margin (%) | -24.85 | -25.19 | -157.53 | -10.56 | -1.85 |
| PBT Margin (%) | -27.39 | -26.82 | -176.72 | -27.32 | -8.10 |
| Net Profit Margin (%) | -27.48 | -30.48 | -175.59 | -28.50 | -8.34 |
| NP After MI And SOA Margin (%) | -27.48 | -30.48 | -175.59 | -28.50 | -8.34 |
| Return on Networth / Equity (%) | 0.00 | 0.00 | -23087.35 | -20.73 | -18.26 |
| Return on Capital Employeed (%) | -5.63 | -6.94 | -52.25 | -2.80 | -1.68 |
| Return On Assets (%) | -3.47 | -4.77 | -33.24 | -5.34 | -5.57 |
| Long Term Debt / Equity (X) | -0.86 | -1.46 | 43.79 | 0.18 | 0.14 |
| Total Debt / Equity (X) | -5.14 | -8.67 | 266.03 | 1.10 | 0.64 |
| Asset Turnover Ratio (%) | 0.12 | 0.15 | 0.16 | 0.18 | 0.12 |
| Current Ratio (X) | 0.80 | 0.83 | 0.78 | 1.36 | 1.55 |
| Quick Ratio (X) | 0.65 | 0.67 | 0.59 | 0.71 | 0.80 |
| Inventory Turnover Ratio (X) | 1.89 | 1.25 | 1.17 | 0.57 | 0.24 |
| Interest Coverage Ratio (X) | -2.94 | -7.25 | -5.19 | -0.17 | 0.73 |
| Interest Coverage Ratio (Post Tax) (X) | -9.85 | -15.29 | -8.15 | -0.70 | -0.33 |
| Enterprise Value (Cr.) | 0.00 | 0.00 | 430.11 | 471.51 | 378.03 |
| EV / Net Operating Revenue (X) | 0.00 | 0.00 | 2.30 | 1.99 | 0.43 |
| EV / EBITDA (X) | 0.00 | 0.00 | -2.31 | -69.44 | 9.57 |
| MarketCap / Net Operating Revenue (X) | 0.00 | 0.00 | 0.29 | 0.50 | 0.15 |
| Price / BV (X) | 0.00 | 0.00 | 38.87 | 0.36 | 0.33 |
| Price / Net Operating Revenue (X) | 0.00 | 0.00 | 0.29 | 0.50 | 0.15 |
| EarningsYield | 0.00 | 0.00 | -5.94 | -0.56 | -0.54 |
After reviewing the key financial ratios for Vivimed Labs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 5. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For Diluted EPS (Rs.), as of Mar 25, the value is -3.74. This value is below the healthy minimum of 5. It has increased from -5.32 (Mar 24) to -3.74, marking an increase of 1.58.
- For Cash EPS (Rs.), as of Mar 25, the value is -1.42. This value is below the healthy minimum of 3. It has increased from -3.08 (Mar 24) to -1.42, marking an increase of 1.66.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -8.82. It has decreased from -5.24 (Mar 24) to -8.82, marking a decrease of 3.58.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -4.24. It has decreased from -0.65 (Mar 24) to -4.24, marking a decrease of 3.59.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 14.02. It has decreased from 17.98 (Mar 24) to 14.02, marking a decrease of 3.96.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -1.05. This value is below the healthy minimum of 2. It has increased from -2.13 (Mar 24) to -1.05, marking an increase of 1.08.
- For PBIT / Share (Rs.), as of Mar 25, the value is -3.49. This value is below the healthy minimum of 0. It has increased from -4.53 (Mar 24) to -3.49, marking an increase of 1.04.
- For PBT / Share (Rs.), as of Mar 25, the value is -3.84. This value is below the healthy minimum of 0. It has increased from -4.82 (Mar 24) to -3.84, marking an increase of 0.98.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 2. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -3.85. This value is below the healthy minimum of 2. It has increased from -5.48 (Mar 24) to -3.85, marking an increase of 1.63.
- For PBDIT Margin (%), as of Mar 25, the value is -7.46. This value is below the healthy minimum of 10. It has increased from -11.82 (Mar 24) to -7.46, marking an increase of 4.36.
- For PBIT Margin (%), as of Mar 25, the value is -24.85. This value is below the healthy minimum of 10. It has increased from -25.19 (Mar 24) to -24.85, marking an increase of 0.34.
- For PBT Margin (%), as of Mar 25, the value is -27.39. This value is below the healthy minimum of 10. It has decreased from -26.82 (Mar 24) to -27.39, marking a decrease of 0.57.
- For Net Profit Margin (%), as of Mar 25, the value is -27.48. This value is below the healthy minimum of 5. It has increased from -30.48 (Mar 24) to -27.48, marking an increase of 3.00.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -27.48. This value is below the healthy minimum of 8. It has increased from -30.48 (Mar 24) to -27.48, marking an increase of 3.00.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Return on Capital Employeed (%), as of Mar 25, the value is -5.63. This value is below the healthy minimum of 10. It has increased from -6.94 (Mar 24) to -5.63, marking an increase of 1.31.
- For Return On Assets (%), as of Mar 25, the value is -3.47. This value is below the healthy minimum of 5. It has increased from -4.77 (Mar 24) to -3.47, marking an increase of 1.30.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.86. This value is below the healthy minimum of 0.2. It has increased from -1.46 (Mar 24) to -0.86, marking an increase of 0.60.
- For Total Debt / Equity (X), as of Mar 25, the value is -5.14. This value is within the healthy range. It has increased from -8.67 (Mar 24) to -5.14, marking an increase of 3.53.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.12. It has decreased from 0.15 (Mar 24) to 0.12, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1.5. It has decreased from 0.83 (Mar 24) to 0.80, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.65. This value is below the healthy minimum of 1. It has decreased from 0.67 (Mar 24) to 0.65, marking a decrease of 0.02.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.89. This value is below the healthy minimum of 4. It has increased from 1.25 (Mar 24) to 1.89, marking an increase of 0.64.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.94. This value is below the healthy minimum of 3. It has increased from -7.25 (Mar 24) to -2.94, marking an increase of 4.31.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -9.85. This value is below the healthy minimum of 3. It has increased from -15.29 (Mar 24) to -9.85, marking an increase of 5.44.
- For Enterprise Value (Cr.), as of Mar 25, the value is 0.00. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EV / EBITDA (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Vivimed Labs Ltd:
- Net Profit Margin: -27.48%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -5.63% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -9.85
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -5.14
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -27.48%
Fundamental Analysis of Vivimed Labs Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 78/A, Kolhar Industrial Area, Bidar Karnataka 585403 | yugandhar.kopparthi@vivimedlabs.com http://www.vivimedlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sandeep Varalwar | Whole Time Director |
| Dr. Jamalapuram Harigopal | Chairman & Ind.Director |
| Mr. Subhash Varalwar | Non Executive Director |
| Mr. Santosh Varalwar | Managing Director |
| Dr. Manohar Rao Varalwar | Whole Time Director |
| Ms. Aparna Bidarkar | Independent Director |
Vivimed Labs Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹4.90 |
| Previous Day | ₹4.90 |
FAQ
What is the intrinsic value of Vivimed Labs Ltd?
Vivimed Labs Ltd's intrinsic value (as of 19 December 2025) is 10.63 which is 57.98% lower the current market price of 25.30, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 210 Cr. market cap, FY2025-2026 high/low of 29.4/25.2, reserves of ₹-65 Cr, and liabilities of 924 Cr.
What is the Market Cap of Vivimed Labs Ltd?
The Market Cap of Vivimed Labs Ltd is 210 Cr..
What is the current Stock Price of Vivimed Labs Ltd as on 19 December 2025?
The current stock price of Vivimed Labs Ltd as on 19 December 2025 is 25.3.
What is the High / Low of Vivimed Labs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Vivimed Labs Ltd stocks is 29.4/25.2.
What is the Stock P/E of Vivimed Labs Ltd?
The Stock P/E of Vivimed Labs Ltd is .
What is the Book Value of Vivimed Labs Ltd?
The Book Value of Vivimed Labs Ltd is 5.79.
What is the Dividend Yield of Vivimed Labs Ltd?
The Dividend Yield of Vivimed Labs Ltd is 0.00 %.
What is the ROCE of Vivimed Labs Ltd?
The ROCE of Vivimed Labs Ltd is 8.10 %.
What is the ROE of Vivimed Labs Ltd?
The ROE of Vivimed Labs Ltd is %.
What is the Face Value of Vivimed Labs Ltd?
The Face Value of Vivimed Labs Ltd is 2.00.